ZYBERNO
Stock Report
Updated Jun 8, 2026

Biophytis SA (BPTSY)

Healthcare • Over The Counter

$0.25

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
0.0/100
POOR BUSINESS
Biophytis SA (BPTSY) scores 0/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-168.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Biophytis SA (BPTSY) stock report — Zyberno Score 0/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.25
Market Cap:$260.12M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$257.42M
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:7.5%
Fundamental Growth Rate (g):-12.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.72x
Quick Ratio:0.72x
Cash Ratio:0.45x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-8.78x
Times Interest Earned:-8.78

Capital Structure (4)

Working Capital:-4,091,460.00
Cash And Cash Equivalents:6,479,988.00
Long Term Debt:$3.78M
Net Debt:-$2.70M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$16.68M

Bottom Line Performance (3)

-$19.82M
Income Before Tax:$0.00
Ebitda Ttm:-15,748,920.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$93.12K
Interest Expense:1,900,812.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$13.92M
Current Assets:$10.30M
Ppe Net:679,776.00
Goodwill:0.00
Intangible Assets:$3.07M

Liability Structure (4)

Total Liabilities:18,448,236.00
Current Liabilities:14,392,860.00
Long Term Debt:$3.78M
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$4.53M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,276,288.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$14.98M$0.00

Investment Activities (1)

Investing Cash Flow:$430.68K

Financing Activities (3)

Financing Cash Flow:$8.18M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.02

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.01

Book Value & Capital (2)

Book Value Per Share:-$0.00
Cash Per Share:0.01

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:7.5%
Fundamental Growth Rate (g):-12.6%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:BPTSY
Company Name:Biophytis SA
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.04B
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 15:32:06 UTC
Data Timestamp:2026-06-08T15:32:06.608262
Scroll to Top